Valuation: Annexon, Inc.

Market Cap 973M 851M 785M 726M 1.38B 92.9B 1.4B 9.4B 3.69B 45.62B 3.65B 3.57B 158B P/E 2026 *
-6.33x
P/E 2027 * -7.58x
Enterprise Value 879M 769M 709M 656M 1.24B 83.88B 1.27B 8.49B 3.33B 41.19B 3.3B 3.23B 143B EV / Sales 2026 *
-
EV / Sales 2027 * 16.8x
Free-Float
93.57%
Yield 2026 *
-
Yield 2027 * -
1 day-0.34%
1 week+8.79%
Current month+4.03%
1 month+14.23%
3 months-3.26%
6 months+13.14%
Current year+18.33%
1 week 5.39
Extreme 5.39
6.51
1 month 4.46
Extreme 4.46
6.51
Current year 4.46
Extreme 4.46
7.18
1 year 2.03
Extreme 2.03
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.81
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 65 01/12/2014
Director/Board Member 67 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
06-11Free

Director

65,000 0.0397%
06-11Free

Director

65,000 0.0397%
06-11Fiscal year

Chief Technology Officer

61,292 0.0374%
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%+8.79%+114.44%+68.75% 973M
-0.63%-4.72%+63.08%+125.14% 56.98B
+4.91%-0.19%+73.70%+92.14% 53.58B
+1.48%+5.97%+22.59%+495.47% 25.63B
-0.59%-4.68%-16.82%-12.99% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-1.53%+1.66%+36.21%-25.66% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+3.51%+53.81% - 14.13B
+1.76%+2.24%+29.57%+195.70% 14.35B
Average +0.94%+1.65%+62.73%+142.95% 24.32B
Weighted average by Cap. +1.26%-0.27%+57.36%+142.33%

Financials

2026 *2027 *
Net sales - 40.5M 35.43M 32.67M 30.23M 57.37M 3.87B 58.33M 391M 153M 1.9B 152M 149M 6.58B
Net income -188M -165M -152M -141M -267M -17.98B -271M -1.82B -713M -8.83B -707M -692M -30.59B -180M -157M -145M -134M -254M -17.14B -259M -1.74B -680M -8.42B -674M -660M -29.16B
Net Debt -94.47M -82.64M -76.21M -70.51M -134M -9.02B -136M -913M -358M -4.43B -355M -347M -15.34B -292M -255M -235M -218M -414M -27.86B -420M -2.82B -1.11B -13.68B -1.1B -1.07B -47.39B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
09/07/26 $5.940 -0.34% 4,836,228
08/07/26 $5.960 -7.31% 7,548,993
07/07/26 $6.430 +7.89% 5,759,444
06/07/26 $5.960 +9.16% 6,778,989
02/07/26 $5.460 -1.62% 2,561,838
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.940USD
Average target price
13.12USD
Spread / Average Target
+120.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock